Managing Myeloma
- 2009-12-15 - New Treatment for Multiple Myeloma Shows Promise
- 2009-12-14 - Denosumab May Be More Effective Than Zometa® for Prevention of Complications Due to Breast Cancer Bone Metastases
- 2009-12-11 - Biotech giant drops Seattle Genetics drug program
- 2009-12-10 - Multiple Myeloma Research Consortium (MMRC) Honors Dana-Farber Cancer Institute with 2009 Center of the Year Award:Kenneth Anderson, MD, and Paul Richardson, MD Managing Myeloma Advisory Board Chair and Contributing Faculty Member Respectively
- 2009-12-09 - High Hopes Remain for Celgene's Revlimid Even as Stocks Fall
- 2009-12-09 - Survival Greater Than 10 Years In Multiple Myeloma Is Related To Longer Treatment Duration (ASH 2009)
- 2009-12-09 - ASH: Relapsed-Refractory Myeloma Responds to Targeted Agent Carfilzomib
- 2009-12-09 - Bortezomib "boosts myeloma treatment"-Pharmacy Europe
- 2009-12-09 - Post-ASH 209: Drug promising in immune system therapy
- 2009-12-09 - Rising From the ASHes-The Motley Fool
- 2009-12-08 - ASH 2009 NEWS FLASH: Bortezomib patients live longer in myeloma study- Reduced risk of death 35 pct over standard drugs alone
- 2009-12-08 - Post ASH 2009, Celgene shares fall on Lenalidomide study (MM-015) data concern
- 2009-12-07 - ASH 2009 NEWS FLASH:First Randomized Study Comparing All-Oral Lenalidomide Regimen Compared to Autologous Stem Cell Transplant Presented
- 2009-12-07 - Breaking News: Celgene to Buy Gloucester Pharmaceuticals
- 2009-12-06 - ASH 2009 NEWS FLASH: Multiple Myeloma Treatment Costs Vary Widely